TOP STORIES FROM ESMO24
First-line immunotherapy combination improves overall survival in HER2-positive metastatic G/GEJ adenocarcinoma
Final analysis of the KEYNOTE-811 trial reports positive findings when adding pembrolizumab to trastuzumab and chemotherapy in treatment-naïve patients
Study results further support the use of neoadjuvant immunotherapy in dMMR colon cancer
Three-year disease-free survival data from NICHE-2 and findings from NICHE-3 add to current knowledge on the benefits of immune checkpoint inhibition in this setting
Long-term survival benefits reported with neoadjuvant immunotherapy combinations in stage III melanoma
Neoadjuvant immunotherapy combinations were associated with high long-term survival rates and were superior to adjuvant nivolumab in patients with resectable melanoma, according to a phase III study and analysis of pooled studies
PRECISION ONCOLOGY
Drug Rediscovery Protocol-like Clinical Trials facilitate access to precision oncology
Data from studies presented highlight the importance of integrating and incorporating comprehensive genomic profiling into clinical practice across a broad range of tumour types
Claudin-targeted antibody–drug conjugates are promising treatments for solid tumours
According to results from several phase I trials, this precision oncology strategy also offers manageable safety
Multi-gene ctDNA profiling effectively matches patients with advanced cancer to targeted therapies
In France, a nationwide programme aims to broaden access to the technology based on the positive results collected so far
EYES TO THE FUTURE
Early-phase studies show therapeutic potential of oncolytic viruses across cancer types
However, presented findings raise some questions about their efficacy in non-injected lesions and the durability of responses
Pioneering the future of immunotherapy: new targets, novel strategies
Several studies report on promising data with immunomodulation and alternative approaches
From precision oncology to molecular prevention – a new role for our profession?
As rapid scientific and technological progress raises hopes of more cancers being intercepted at the earliest stages in the future, ESMO delves deeper into prevention to ensure education and guidance for medical oncologists in this moving field
COLUMNS
The expanding toolbox for immuno-oncology
Novel treatment approaches show encouraging early results in solid tumours, but ways to boost precision immunotherapy are needed
Off-label use of cancer medicines: an option not without challenges
Together with an off-trial use and off-track access to oncology therapies, a consolidated trend is reported in clinical practice despite the uncertainties on efficacy and safety
OPINIONS
How to bridge the gap between palliative care and oncology?
Rita Canario
Physical activity is beneficial for patients with cancer, but also challenging
Gabriella Pravettoni
Rising rates of cancer in young people: nature or nurture?
Shuji Ogino
Overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Myriam Chalabi
Harnessing the power of the gut microbiome in colorectal cancer
Laurence Zitvogel
OPINIONS
How to bridge the gap between palliative care and oncology?
Rita Canario
Physical activity is beneficial for patients with cancer, but also challenging
Gabriella Pravettoni
Rising rates of cancer in young people: nature or nurture?
Shuji Ogino
Overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Myriam Chalabi
Harnessing the power of the gut microbiome in colorectal cancer
Laurence Zitvogel